Douglas Shaffer1, Johnstone Kumwenda2, Huichao Chen3, Victor Akelo4, Francis Angira4, Josphat Kosgei5, Ronald Tonui6, Francis Ssali7, Ashley McKhann3, Evelyn Hogg8, V Ann Stewart9, Sean C Murphy10, Robert Coombs11,12, Robert Schooley13. 1. US Centers for Disease Control and Prevention, Kigali, Rwanda (at the time of research). 2. College of Medicine-Johns Hopkins Project, Blantyre, Malawi. 3. Harvard T.H. Chan School of Public Health, Boston, MA. 4. Kenya Medical Research Institute, Center for Global Health (KEMRI/CGHR)/Emory-CDC CTU, Kisumu, Kenya. 5. Kenya Medical Research Institute/United States Army Medical Research Directorate-Africa/Kenya, Kericho, Kenya. 6. Moi University School of Medicine, Eldoret, Kenya. 7. Joint Clinical Research Center, Kampala, Uganda. 8. Social and Scientific Systems, Inc., A DLH Holdings Company, Silver Spring, MD. 9. Uniformed Services University of the Health Sciences, Bethesda, MD. 10. Departments of Laboratory Medicine and Pathology, University of Washington; Department of Microbiology, University of Washington; Center for Emerging and Re-emerging Infectious Diseases, University of Washington; Seattle, WA. 11. Departments of Laboratory Medicine and Pathology; and. 12. Medicine, University of Washington, Seattle, WA; and. 13. Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA.
Abstract
BACKGROUND: HIV protease inhibitors anti-Plasmodium falciparum activity in adults remains uncertain. METHODS: Adults with HIV CD4+ counts >200 cells/mm3 starting antiretroviral therapy (ART) with P. falciparum subclinical parasitemia (Pf SCP) were randomized 1:1 to (step 1) protease inhibitor lopinavir/ritonavir (LPV/r)-based (arm A) or nonnucleoside reverse transcriptase inhibitor (nNRTI)-based ART (arm B) for 15 days. In step 2, participants received nNRTI-based ART and trimethoprim/sulfamethoxazole prophylaxis for 15 days. P. falciparum SCP clearance was measured by polymerase chain reaction. The Fisher exact test [95% exact confidence interval (CI)] was used to compare proportions of P. falciparum SCP clearance (<10 parasites/μL on 3 occasions within 24 hours) between LPV/r and nNRTI arms at day 15. The Kaplan-Meier method and log-rank test were used to compare time-to-clearance. RESULTS: Fifty-two adults from Kenya, Malawi, and Uganda with a median age = 31 (Q1, Q3: 24-39) years, 33% women, with baseline median CD4+ counts of 324 (259-404) cells/mm3, median HIV-1 RNA viremia of 5.18 log10 copies/mL (4.60-5.71), and median estimated P. falciparum density of 454 parasites/μL (83-2219) enrolled in the study. Forty-nine (94%) participants completed the study. At day 15, there was no statistically significant difference in the proportions of P. falciparum SCP clearance between the LPV/r (23.1% clearance; 6 of the 26) and nNRTI (26.9% clearance; 7 of the 26) arms [between-arm difference 3.9% (95% CI, -21.1% to 28.4%; P = 1.00)]. No significant difference in time-to-clearance was observed between the arms (P = 0.80). CONCLUSIONS: In a small randomized study of adults starting ART with P. falciparum SCP, no statistically significant differences were seen between LPV/r- and nNRTI-based ART in P. falciparum SCP clearance after 15 days of treatment.
BACKGROUND: HIV protease inhibitors anti-Plasmodium falciparum activity in adults remains uncertain. METHODS: Adults with HIV CD4+ counts >200 cells/mm3 starting antiretroviral therapy (ART) with P. falciparum subclinical parasitemia (Pf SCP) were randomized 1:1 to (step 1) protease inhibitor lopinavir/ritonavir (LPV/r)-based (arm A) or nonnucleoside reverse transcriptase inhibitor (nNRTI)-based ART (arm B) for 15 days. In step 2, participants received nNRTI-based ART and trimethoprim/sulfamethoxazole prophylaxis for 15 days. P. falciparum SCP clearance was measured by polymerase chain reaction. The Fisher exact test [95% exact confidence interval (CI)] was used to compare proportions of P. falciparum SCP clearance (<10 parasites/μL on 3 occasions within 24 hours) between LPV/r and nNRTI arms at day 15. The Kaplan-Meier method and log-rank test were used to compare time-to-clearance. RESULTS: Fifty-two adults from Kenya, Malawi, and Uganda with a median age = 31 (Q1, Q3: 24-39) years, 33% women, with baseline median CD4+ counts of 324 (259-404) cells/mm3, median HIV-1 RNA viremia of 5.18 log10 copies/mL (4.60-5.71), and median estimated P. falciparum density of 454 parasites/μL (83-2219) enrolled in the study. Forty-nine (94%) participants completed the study. At day 15, there was no statistically significant difference in the proportions of P. falciparum SCP clearance between the LPV/r (23.1% clearance; 6 of the 26) and nNRTI (26.9% clearance; 7 of the 26) arms [between-arm difference 3.9% (95% CI, -21.1% to 28.4%; P = 1.00)]. No significant difference in time-to-clearance was observed between the arms (P = 0.80). CONCLUSIONS: In a small randomized study of adults starting ART with P. falciparum SCP, no statistically significant differences were seen between LPV/r- and nNRTI-based ART in P. falciparum SCP clearance after 15 days of treatment.
Authors: Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191
Authors: U Lek-Uthai; R Suwanarusk; R Ruengweerayut; T S Skinner-Adams; F Nosten; D L Gardiner; P Boonma; K A Piera; K T Andrews; B Machunter; J S McCarthy; N M Anstey; R N Price; B Russell Journal: Antimicrob Agents Chemother Date: 2008-04-28 Impact factor: 5.191
Authors: Charlotte V Hobbs; Erin E Gabriel; Portia Kamthunzi; Gerald Tegha; Jean Tauzie; Elizabeth Petzold; Linda Barlow-Mosha; Benjamin H Chi; Yonghua Li; Tiina Ilmet; Brian Kirmse; Jillian Neal; Sunil Parikh; Nagamah Deygoo; Patrick Jean Philippe; Lynne Mofenson; William Prescott; Jingyang Chen; Philippa Musoke; Paul Palumbo; Patrick E Duffy; William Borkowsky Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Ronnie P Kasirye; Heiner Grosskurth; Paula Munderi; Jonathan Levin; Zacchaeus Anywaine; Andrew Nunn; Anatoli Kamali; Kathy Baisley Journal: AIDS Date: 2017-02-20 Impact factor: 4.177
Authors: Annette M Seilie; Ming Chang; Amelia E Hanron; Zachary P Billman; Brad C Stone; Kevin Zhou; Tayla M Olsen; Glenda Daza; Jose Ortega; Kurtis R Cruz; Nahum Smith; Sara A Healy; Jillian Neal; Carolyn K Wallis; Lisa Shelton; Tracie VonGoedert Mankowski; Sharon Wong-Madden; Sebastian A Mikolajczak; Ashley M Vaughan; Stefan H I Kappe; Matt Fishbaugher; Will Betz; Mark Kennedy; Jen C C Hume; Angela K Talley; Stephen L Hoffman; Sumana Chakravarty; B Kim Lee Sim; Thomas L Richie; Anna Wald; Christopher V Plowe; Kirsten E Lyke; Matthew Adams; Gary A Fahle; Elliot P Cowan; Patrick E Duffy; James G Kublin; Sean C Murphy Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345